Development of a Novel Prognostic Model for Esophageal Squamous Cell Carcinoma: Insights into Immune Cell...

Area of Science:

• Oncology
• Genomics
• Immunotherapy

Background:

• Esophageal squamous cell carcinoma (ESCC) has a poor prognosis with a five-year survival rate under 20%.
• There is a critical need for enhanced prognostic markers to improve patient outcomes.
• Current therapeutic strategies require refinement for better efficacy.

Purpose of the Study:

• To identify key genes associated with ESCC prognosis.
• To develop a robust prognostic model for stratifying ESCC patients.
• To explore the relationship between the prognostic model and immune responses.

Main Methods:

• Analysis of ESCC-specific gene expression datasets.
• Venn analysis and gene network interactions to identify differentially expressed genes.
• Development of a prognostic model using the COX algorithm and validation with AUC.

Main Results:

• Identification of 23 key differentially expressed genes.
• A 23-gene prognostic model demonstrated high accuracy (3-year AUC = 0.967).
• High-risk patients exhibited poorer outcomes, reduced chemotherapy sensitivity, and distinct immune profiles, including M2 macrophage infiltration and altered immune checkpoint gene expression.

Conclusions:

• The 23-gene model effectively stratifies ESCC patients into distinct risk groups.
• The model correlates with tumor immune microenvironment factors and immune checkpoint gene expression.
• This prognostic tool shows potential for guiding immunotherapy decisions, particularly immune checkpoint blockade, for high-risk ESCC patients.